Vasoactive Intestinal Polypeptide(VIP) corrects Chronic Inflammatory Response Syndrome(CIRS)

[Soundthealarm21]

Author(s)
Ritchie C. Shoemaker, Dennis House, James C. Ryan

ABSTRACT

Exposure in water-damaged buildings (WDB) to airborne bioaerosols including metabolic products of toxigenic fungi, bacteria and actinomycetes; and inflammagens, can lead to a persistent innate immune inflammatory illness. This illness, termed a chronic inflammatory response syndrome (CIRS-WDB), is systemic with symptoms acquired from multiple organ systems. Treatment of CIRS-WDB has progressed rapidly as a better understanding of the inflammatory pathophysiology has led to targeted, sequential therapies. The fundamental basis of uncontrolled innate immune responses, the humoral deficiency of regulatory neuropeptides melanocyte stimulating hormone (MSH) or vasoactive intestinal polypeptide (VIP), seen in over 98% of pa tients, has not consistently responded to any treatment modality. Use of replacement VIP has been attempted anecdotally; VIP replacement therapies show promise in short term studies but longer therapies have not been attempted. Here we report an open label trial of 20 patients with refractory CIRS-WDB illness who took replacement VIP in a nasal spray for at least 18 months with confirmation of durable efficacy and absence of significant side effects. These 20 patients were similar in symptoms and lab find- ings to three previously published cohorts in- volving 1829 patients and 169 controls. Dosage of VIP was titrated downwards from four to zero doses a day to determine minimum effective dose, and retitrated upwards for maximum improvement over time. The trial showed that VIP therapy safely 1) reduced refractory symptoms to equal controls; 2) corrected inflammatory parameters C4a, TGF beta-1, VEGF, MMP9; 3) corrected estradiol, testosterone and 25-OH Vitamin D; 4) returned pulmonary artery systolic pressure (PASP) during exercise to normal; and 5) enhanced quality of life in 100% of trial patients. Subsequent identification of correction of T-regulatory cell levels supports the potential role of VIP in both innate and adaptive immune function.

Does anyone have any experience taking VIP?

 

[Thinktank]

No, but i'll be travelling to the US in a few months to have all Shoemakers biomarkers for biotoxin illness tested.
Very interesting, are you going to try the VIP nasal spray?

 

[Soundthealarm21]

No, but i'll be travelling to the US in a few months to have all Shoemakers biomarkers for biotoxin illness tested.
Very interesting, are you going to try the VIP nasal spray?

I've read some good stuff on it so I'm going to ask my doctor about it. It has peaked my curiosity. Where in the US are you coming to?

 

[steve b]

I first tried VIP a year ago but it had no affect initially because I was still being exposed to mold. After spending a few weeks in a low-mold environment, I find VIP greatly reduces fatigue and cognitive dysfunction. I find it far more effective than anything else I've tried. I'd rank GcMAF the second most effective treatment. I've had CFS since 1997.

 

[CFS_for_19_years]

Here's the link to the full article:

www.survivingmold.com/docs/VIP_published_3_2013.pdf

I found a blog post from someone with CFS who started using VIP:

http://cfsmethylation.blogspot.com/2013/05/vasoactive-intestinal-peptide-vip-my.html

I believe this blog is written by PR member JanisB.